Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Prior authorization leeway will be trimmed while health plans get more money under new federal rules for Medicare Advantage ...

Shares of Apple and Dell Technologies rise after the Trump administration exempts smartphones, computers, memory chips, and ...

Today CMS announced that payments to Medicare Advantage and Part D Prescription Plans would increase by 5.06% next year ...

The Trump administration opted to boost Medicare Advantage rates more than the Biden administration originally offered.

In the long term, bariatric surgery is more cost-effective than new anti-obesity medications, research finds, triggering a ...

Tirzepatide was approved in November 2023 by the US Food and Drug Administration (FDA) (Zepbound) and in the EU in June 2024 ...

The increasing use of GLP-1 medications for weight loss is leading to significant changes in food preferences, with users ...

Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in ad ...

The study, led by Dr Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to ...